Longevity & Biohacking · Dr. Emily Hart · 6 November 2026

Longevity supplement improved blood vessel function in trial

Longevity supplement improved blood vessel function in trial

A longevity supplement improved blood vessel function in a University of Surrey trial: adults taking NOVOS Core saw stronger artery dilation, lower arterial stiffness, and an adjusted 6.1 mmHg drop in systolic blood pressure after six months versus placebo, though lipids were unchanged and independent replication is still needed.

Key Takeaways

What did the longevity supplement trial actually find?

Researchers led by Christian Heiss at the University of Surrey tested NOVOS Core in a randomized, double-blind, placebo-controlled study published in European Heart Journal Open. According to reporting from Lifespan.io, the multi-ingredient powder was linked to better artery function and lower systolic blood pressure.

Sixty-one generally healthy, nonsmoking adults were assigned to supplement or placebo and took one 15-gram daily dose. The primary analysis included 43 people. Average baseline blood pressure was roughly 128/75 mmHg in the supplement group and 125/75 mmHg in placebo, so this was not a severe hypertension cohort.

At six months, flow-mediated dilation—the study’s primary endpoint—rose about 2.6 percentage points with NOVOS Core (from roughly 5.5% to 8.1%) while staying steady on placebo. The adjusted improvement versus placebo was 2.9 points. Systolic pressure fell 8.5 mmHg on the supplement versus 1.5 mmHg on placebo (adjusted difference 6.1 mmHg).

Why do these blood vessel changes matter?

Aging often blunts the endothelium’s response to blood flow and stiffens arteries, which can push systolic pressure up. Flow-mediated dilation and pulse wave velocity are widely used markers of that vascular aging.

In this trial, pulse wave velocity dropped 0.78 m/s with the supplement and rose 0.56 m/s on placebo at six months (adjusted between-group difference −1.18 m/s). An acute one-hour pulse wave velocity difference favored the supplement but was not significant, while acute dilation gains were clear. Blood lipids did not drive the result: total, LDL, HDL cholesterol, and triglycerides showed no significant between-group differences.

For readers following longevity and biohacking research, a multi-component formula moving several vascular markers in humans is notable—even if mechanism and ingredient-level credit remain unknown.

Should you trust a longevity supplement after one study?

NOVOS Core blends glycine, calcium alpha-ketoglutarate, glucosamine sulfate, magnesium malate, vitamin C, L-theanine, fisetin, pterostilbene, hyaluronic acid, lithium aspartate, and rhodiola and ginger extracts. The trial tested the mixture as a whole, so which ingredients matter is unclear. NOVOS helped fund the work and supplied product and placebo.

Limitations matter. Most attrition was unexplained, and the control group was older (about 60 versus 53 at enrollment). Blood pressure came from two study days only, so day-to-day noise is a concern. Longevity physician Brad Stanfield, who was not involved, called the effect size surprisingly large but stressed replication given dropout and the age gap.

Bottom line: one well-controlled human trial associated NOVOS Core with better endothelial function, lower arterial stiffness, and lower systolic pressure after six months—promising, not proof you should start a powder tomorrow.

← Open in blast feed